Karyopharm Therapeutics | KPTI - Gewinn Vor Steuern





Gewinn Vor Steuern Veränderung Datum
AbbVie USD 7.61B 2.04B 2026-06
Abbott USD 2.39B 27M 2026-03
Amgen USD 2.08B 570M 2026-03
AstraZeneca USD 4.81B 894M 2026-06
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Eli Lilly USD 8.85B 583.8M 2026-03
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
GlaxoSmithKline GBP 2.68B 532M 2026-06
Incyte USD 751.51M 407.91M 2026-06
J&J USD 8.66B 839M 2026-06
Karyopharm Therapeutics USD -22.39M 17.51M 2026-03
MacroGenics USD -36.77M 21.84M 2026-03
Merck USD -3.53B 6.95B 2026-03
Nektar Therapeutics USD -43.09M 8.39M 2026-03
Novartis USD 4.27B 430M 2026-06
Novartis USD 3.84B 1.33B 2026-03
Pfizer USD -653M 5.84B 2026-06
Regeneron Pharmaceuticals USD 1.53B 696.6M 2026-06
Roche Holding CHF 11.17B 6.38B 2026-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Takeda JPY 162.72B 215.2B 2026-06
Tectonic Therapeutic USD -18.97M 63K 2025-12
TG Therapeutics USD 10.23M 10.13M 2026-06
Ultragenyx Pharmaceutical USD -91M 93M 2026-06
Xencor USD -21.92M 106.72M 2026-06